KYORIN Pharmaceutical Reshapes Board and Audit Team in June Leadership Overhaul

KYORIN Pharmaceutical Co.,Ltd. ( (JP:4569) ) just unveiled an announcement.

KYORIN Pharmaceutical Co., Ltd. has announced a reshuffle of its governance structure, including new director and auditor appointments effective June 19, 2026, subject to approval at the upcoming Ordinary General Meeting of Shareholders and subsequent board meeting. Executive Director and CCO Noriaki Tamura is slated to become Executive Director, while outside director candidate Tomohiro Okanoya and new auditors Katsuhiro Hamada and Yutaka Abe will join as part of the refreshed oversight team.

The company also detailed the retirement of Executive Director and CMO Michiro Onota, who will become an advisor, alongside retiring outside director Noriyuki Shikanai and senior corporate auditor Tomiharu Matsumoto and outside auditor Yukio Ikemura, signaling a generational handover in leadership and audit functions. In tandem, KYORIN will appoint Kenichi Nakamura as Managing Corporate Officer and CMO in charge of Quality Assurance & Reliability and supply chain management, reinforcing operational governance and aligning leadership roles with its quality and logistics priorities.

More about KYORIN Pharmaceutical Co.,Ltd.

KYORIN Pharmaceutical Co., Ltd. is a Japan-based pharmaceutical company listed on the Tokyo Stock Exchange Prime Market under security code 4569. The company focuses on developing, manufacturing and marketing prescription drugs and related healthcare products, with particular attention to sales, marketing, quality assurance and supply chain management across its domestic and group operations.

Average Trading Volume: 104,171

Technical Sentiment Signal: Buy

Current Market Cap: Yen81.59B

For a thorough assessment of 4569 stock, go to TipRanks’ Stock Analysis page.